

Freedom of Information Request	FOI 22-366	30 th August 2022
--------------------------------	------------	------------------------------

Q1. How many patients were treated in last 4 months by the Dermatology department (for any disease) with each of the following:

- **Abrocitinib**
- **Acitretin**
- **Alitretinoin**
- **Azathioprine**
- **Baricitinib**
- **Ciclosporin**
- **Dupilumab**
- **Methotrexate**
- **Mycophenolate mofetil**
- **Pimecrolimus**
- **Tacrolimus ointment**
- **Tralokinumab**
- **Upadacitinib**

Please find below the quantities dispensed from the Health Board pharmacies for the period April 2022 – July 2022 for dermatology.

Please note the Health Board is only able to supply information by quantity and not by the number of patients treated:

Description	Qty
DUPILUMAB (DUPIXENT) 200 mg in 1.14mL Pre-Filled Pen 2 Pre-Filled Pen Pack	9
DUPILUMAB (DUPIXENT) 200 mg in 1.14mL Pre-Filled Syringe 2 Pre-Filled Syringe Pack	6
DUPILUMAB (DUPIXENT) 300 mg in 2mL Pre-Filled Pen 2 Pre-Filled Pen Pack	91
DUPILUMAB (DUPIXENT) 300 mg in 2mL Pre-Filled Syringe 2 Pre-Filled Syringe Pack	92
METHOTREXATE (METOJECT) 10 mg in 0.2mL Pre-Filled Pen 1 Pre-Filled Pen Pack	7

Q2. Of the patients treated in the last 4 months with any of the products listed in Q1, how many patients were paediatric (age 17 or under)?

The Health Board does not record this information centrally. Therefore, in order to comply with your request, the Health Board has established that this would exceed the appropriate costs limit under Section 12 of the Freedom of Information Act 2000 which is currently £450. As you will be aware this is not an exemption which requires us to consider the application

of the public interest test. We have calculated that it would take in excess of 18 hours to review the record of each patient.

Q3. How many patients were treated in the last 4 months with phototherapy (UVB or PUVA) for atopic dermatitis ONLY?

Please refer to Q2.